Skip to main content
. 1998 Sep;72(9):7476–7483. doi: 10.1128/jvi.72.9.7476-7483.1998

TABLE 5.

Cytolytic activity of lesion-derived, tegument-specific CD4 TCC, with summary of fine specificity and HLA restriction

TCC Specificitya HLA restrictionb % Specific releasec with the following cytolysis assay target:
Auto HSV-2 Auto peptide Auto mock Allo HSV-2 Allo peptide Allo mock
Newly reported epitopes
 4.2E1 VP22 105-126 DPB1*2001 20.7 44.2 −4.1 −2.9 −1.7 4.6
 ESL4.9 VP22 187-206 DRd −0.6 20.2 1.3 0 0 0
 ESL2.20 UL21 148-181 DRd 2.7 NA 0.9 0 NA 0
 1.L3D5.10.8 VP22 125-146 DRe 1.1 61.1 −0.3 −0.4 −0.6 −0.4
 1.L3D5.10.12 VP22 125-146 DRe 2.5 57.6 1.6 −0.1 −2.5 −1.4
 RH.13 VP16 185-197 DR4 62.5 55.2 −0.9 9.6 0.3 1.8
 KM.7 VP16 209-221 DR2 38.7 43.6 2.7 −2.2 4.3 −1.1
 BM.17 VP16 437-449 DQB1*0501 10.1 28.5 −0.3 ND ND ND
 SB.17 VP16 437-449 DQB1*0501 48.7 60.6 5.4 ND ND ND
 2.3 UL50 118-250 DRB1*0301 0.8 NA 0 1.1 NA 0
Previously described epitopes
 ESL4.34 VP16 393-405 DRB1*0402 2.1 10.4 1.0 0.5 0.6 0.3
 ESL3.334 VP16 430-444 DQB1*0302 12.3 33.6 0.7 1.4 0.3 2.2
 1A.B.25 VP16 431-440 DQB1*0201 24.3 42.2 1.9 1.7 2.1 −0.4
a

Indicates peptide used (1 μM) to load targets in CTL assay for selected TCC. 

b

Maximum extent of definition of HLA restricting locus and/or allele. Subjects 6 and 7 were typed serologically; others were typed at the DNA level. 

c

At an effector-to-target ratio of 20:1, except for ESL4.34 (10:1). Auto, autologous EBV-LCL as target cells; allo, allogeneic EBV-LCL mismatched at the relevant HLA locus (if known) or mismatched at HLA-DR and -DQ. NA, not available, since epitope mapping was not done and synthetic antigenic peptide was not made; ND, not done. 

d

Subject is heterozygous for HLA DRB1*0402 and DRB1*1301, and restricting allele has not been determined. 

e

Subject is heterozygous for HLA DRB1*0301 and DRB1*1102, and restricting allele has not been determined.